Related by context. All words. (Click for frequent words.) 63 CARDIA 61 nondepressed 60 nonpregnant women 60 THIS STUDY randomly assigned 60 nulliparous women 60 adenotonsillectomy 60 THIS STUDY analyzed 60 recurrent VTE 60 underwent bariatric surgery 60 umol L 59 BMI ≥ 59 mild cognitive impairments 59 Polycystic ovary syndrome PCOS 59 NHANES III 59 Major depressive disorder 59 MMSE scores 59 underwent CABG 59 Young Adults CARDIA 58 REYATAZ r arm 58 euthymic patients 58 aged ≥ 58 PREZISTA ritonavir 58 #q# deletion syndrome 58 dysglycemia 58 T1DM 58 flutamide 58 Netherlands Cohort Study 58 HIV seronegative 58 Wisconsin Sleep Cohort 58 adjunctive ABILIFY 58 baseline HbA1c 58 elevated triglyceride levels 58 adjunctive placebo 58 undergone radical prostatectomy 58 Health Initiative Observational 58 psychiatric comorbidities 58 multiple logistic regression 58 PREZISTA r arm 57 symptomatic BPH 57 PON1 activity 57 cerebral microbleeds 57 PREZISTA r 57 overnight polysomnography 57 RLS sufferers 57 CAVEATS 57 retrospective cohort 57 LUTS 57 elevated ALT 57 STRATEGY FOR AN OPEN 57 microalbumin 57 univariate analyzes 57 nonvertebral fractures 57 nonobese 57 comorbid depression 57 HRQL 57 overactive bladder symptoms 57 generalized edema 57 bivariate analyzes 57 femoral neck BMD 57 retrospective cohort study 57 logistic regression analysis 57 prospective cohort 57 PRADAXA #mg 57 reflux disease GERD 57 paroxetine Paxil 57 Index CDAI 57 Replication NCS R 57 longitudinal observational study 57 Baltimore Longitudinal Study 57 CARDIA study 57 antidiabetic medication 56 habitual snoring 56 opioid dependent 56 typical antipsychotics 56 Non Alcoholic Steatohepatitis 56 hip BMD 56 perimenopausal women 56 prescribed isotretinoin 56 Incontinence Impact Questionnaire 56 Framingham Offspring Study 56 Juvenile Idiopathic Arthritis 56 comorbid ADHD 56 venlafaxine XR 56 unipolar depression 56 % CI #.#-#.# [003] 56 episodic migraine 56 Carotid Revascularization Endarterectomy vs. 56 Complication rates 56 underwent radical prostatectomy 56 Depressive symptoms 56 Framingham Offspring 56 fasting insulin 56 COPD exacerbation 56 Generalized Anxiety Disorder 56 venlafaxine Effexor 56 % CI #.#-#.# [008] 56 NIH CPSI 56 lopinavir r arm 56 diabetes mellitus DM 56 preintervention 56 CIMZIA TM certolizumab pegol 56 relapsed MM 56 Arch Intern Med 56 efavirenz EFV 56 serum IGF 56 SGPT 56 nondemented 56 Skin sterol 56 aneurysmal subarachnoid hemorrhage 56 hypoglycemic episodes 56 longitudinal cohort study 56 intermittent exotropia 56 asymptomatic carotid stenosis 56 Prehypertension 56 male Wistar rats 55 VIIBRYD 55 persistent pulmonary hypertension 55 MADRS score 55 ALT flares 55 odds ratios ORs 55 aldosterone antagonist 55 impulsivity characteristic 55 BMI z 55 Women Ischemia Syndrome 55 advanced neoplasia 55 polycystic ovary syndrome PCOS 55 hypophosphatemia 55 TEAEs 55 risperidone Risperdal 55 Prostate Lung Colorectal 55 Logistic regression 55 mcg QD 55 C1 INH deficiency 55 risperidone olanzapine 55 subtrochanteric 55 unprovoked seizures 55 elevated serum creatinine 55 abstinent alcoholics 55 Screening Trial 55 nondiabetic 55 mild renal insufficiency 55 serum selenium 55 hypertension diabetes mellitus 55 HIV uninfected 55 CrCl 55 schizophrenia schizoaffective disorder 55 esophageal reflux 55 IDDM 55 Communities ARIC study 55 hours postdose 55 attention-deficit/hyperactivity disorder ADHD 55 sociodemographic characteristics 55 FluCAM arm 55 BRCA2 mutation carriers 55 atrophic gastritis 55 conditional logistic regression 55 Fatty Liver Disease 55 % CI #.#-#.# [007] 55 extrapyramidal symptoms 55 NHANES #-# 55 URTI 55 METHODS 55 abnormal lipid 55 urolithiasis 55 normotensive 55 subclinical hypothyroidism 55 DSM IV diagnosis 55 Subgroup analysis 55 probands 55 dietary questionnaires 55 arterial thromboembolic events 55 nonexposed 55 placebo controlled studies 54 REYATAZ ® 54 observational cohort study 54 randomized multicenter trial 54 hypercholesterolaemia 54 prospective observational cohort 54 rosuvastatin Crestor 54 #mg/dL [001] 54 NOLVADEX 54 vaginal hysterectomy 54 psychiatric morbidity 54 EDSS score 54 DPNP 54 mg/m2 dose 54 rFVIIa 54 advanced adenoma 54 conventional antipsychotics 54 multivariate logistic regression 54 undergone bariatric surgery 54 nondiabetic patients 54 onset diabetes mellitus 54 logistic regression model 54 mg BID dose 54 oxycodone CR 54 chronic prostatitis 54 mg Pycnogenol 54 preoperatively 54 patients undergoing percutaneous 54 habitual snorers 54 amoxicillin clavulanate 54 histological subtype 54 IgA deficiency 54 logistic regression models 54 spirometric 54 sd = 54 bupropion SR 54 bipolar mania trials 54 overweight sedentary 54 Cholesterol Levels SPARCL 54 fasting serum 54 fasting triglyceride levels 54 Swedish Mammography Cohort 54 MMSE score 54 neurodevelopmental outcome 54 quetiapine risperidone 54 CHD CVD 54 VADT 54 Normative Aging Study 54 thyrotropin levels 54 cognitively normal 54 NATRECOR R 54 autoantibody positive 54 GH deficiency 54 narcolepsy cataplexy 54 multivariable adjusted 54 proband 54 concomitant medications 54 colorectal adenoma 54 microalbumin test 54 mL/min/#.# m 2 54 HBeAg positive 54 postoperative complication 54 DAS# CRP 54 cryptogenic 54 conjunctival hyperemia 54 nonsevere 54 hypogonadal men 54 Digital Mammographic Imaging 54 VaD 54 RLAI 54 Acute Coronary Syndromes 54 newer antipsychotic medications 54 colorectal adenomas 54 adolescent females 54 NNT = 54 Efficacy endpoints 54 Study ARIC 54 nonvertebral fracture 54 Postmenopausal 54 seroconverted 54 serum leptin 54 Myelodysplastic syndromes MDS 54 systolic hypertension 54 postmenopausal osteoporotic women 54 recurrent UTI 54 persistent wheezing 54 substudy 54 confidence interval #.#-#.# 54 suicide attempters 54 PERMP 54 DRD2 54 monoinfected patients 54 lacunar 54 hyperactive impulsive 54 TMC# r 53 affective psychoses 53 BoNTA 53 Relieve Depression 53 ug dose 53 liver biopsies 53 testosterone supplementation 53 nonmelanoma skin cancers 53 perioperatively 53 pimecrolimus cream 53 n = 53 randomized controlled trials RCTs 53 beta blocker therapy 53 glycated hemoglobin levels 53 APTIVUS r 53 Pooled Analysis 53 polycystic ovarian syndrome PCOS 53 lipid lowering agents 53 hippocampal volumes 53 confidence intervals CIs 53 prospective longitudinal 53 posttreatment 53 calculated creatinine clearance 53 Placebo Controlled Study 53 conjugated equine estrogens 53 Comorbid 53 adenomatous polyps 53 β blockers 53 Logistic regression analysis 53 primary hypercholesterolemia 53 Oral Fingolimod 53 undergoing radical prostatectomy 53 prospectively randomized 53 prepubertal 53 Baseline characteristics 53 Cognitive impairment 53 shorter telomere length 53 schizophreniform disorder 53 histologically proven 53 Liver biopsies 53 occipital regions 53 affective disorders 53 NPH insulin 53 aspartate aminotransferase AST 53 neurocognitive function 53 antiretroviral naïve 53 liver transplant recipients 53 biochemical relapse 53 endoscopic examinations 53 nortriptyline Pamelor 53 neurocognitive functioning 53 fluoroscopy guided 53 Multivariate analysis 53 Neonates 53 generalized anxiety disorder GAD 53 Avandia Actos 53 PLX STROKE targeting 53 #mg/day [001] 53 recurrent venous thromboembolism 53 Heavy menstrual bleeding 53 STEP BD 53 MetS 53 ELBW infants 53 imaging fMRI scans 53 parous women 53 Treated Patients 53 prostate cancer CaP 53 Sleep disordered breathing 53 Expanded Disability Status 53 REGARDS 53 atopic 53 serum lipid levels 53 Multiple logistic regression 53 poor metabolizers 53 Comorbidities 53 ACCOMPLISH 53 % CI #.#-#.# [006] 53 sedentary postmenopausal 53 Irritable bowel syndrome 53 nonobese patients 53 underwent surgical resection 53 SSRI SNRI 53 GBA mutations 53 Non Alcoholic Fatty 53 Invasive Breast Cancer 53 Major Depressive Disorder 53 Sociodemographic 53 sensory neuropathy 53 tricyclic antidepressants TCAs 53 prospective observational 53 syndromal 53 OSAHS 53 Renal dysfunction 53 Genetic variants 53 drank pomegranate juice 53 elevated LDL cholesterol 53 perioperative complications 53 Child Behavior Checklist 53 neuropsychological functioning 53 histologically confirmed 53 bowel polyps 53 Insulin sensitivity 53 cardiorespiratory fitness 53 HIV HCV coinfected 53 hemoglobin A1c levels 53 recurrent wheezing 53 Sprague Dawley rats 53 premenopausal 53 subanalysis 53 oxcarbazepine 53 infliximab Remicade 53 mmHg diastolic 53 baseline A1C 53 THE MISSOURI DEPARTMENT 53 antihypertensive medications 53 Randomized Controlled Trials 53 placebo PBO 53 cerebral infarctions 53 reflux symptoms 53 nighttime awakenings 53 Atherosclerosis Risk 53 null responder HCV 53 prescribed antipsychotics 53 Hurthle cell 53 fatigue asthenia 53 #q# deletion 53 euthymic 53 estimated glomerular filtration 52 premorbid 52 Non Responders 52 onset seizures 52 affective disorder 52 CIN3 52 symptomatic hyponatremia 52 subclinical atherosclerosis 52 ARIXTRA 52 plasma homocysteine levels 52 % CI #.#-#.# [004] 52 HBeAg negative 52 WHEL 52 Nonalcoholic Fatty Liver Disease 52 solifenacin 52 tic disorders 52 multicentre randomized double 52 logistic regression analyzes 52 Cognitive Impairment 52 prehypertensive 52 zolmitriptan 52 placebo controlled trials 52 Genotypes 52 recurrent acute pancreatitis 52 octreotide LAR 52 suboptimal adherence 52 depressive symptomatology 52 asthma exacerbation 52 neurologic complications 52 BMI percentile 52 atherogenic dyslipidemia 52 underwent coronary angiography 52 triiodothyronine 52 univariate 52 plasma folate 52 ABC/3TC 52 affective psychosis 52 Severe Primary IGFD 52 Premenopausal 52 elevated fasting glucose 52 undergone hysterectomy 52 episodic migraine sufferers 52 HCV SPRINT 52 interquartile range 52 Prostate Cancer Prevention 52 F FDG PET 52 detrusor overactivity 52 SRBD 52 lamivudine monotherapy 52 dyskinesia PD LID 52 Subtypes 52 PsA 52 ABCB1 52 Univariate 52 angiographically 52 Urogenital Distress Inventory 52 #.#ng/ml 52 dysthymia 52 EDSS scores 52 endometrial carcinoma 52 placebo controlled clinical 52 NCCTG N# 52 elevated triglycerides 52 severe renal impairment 52 carotid stenosis 52 atazanavir ritonavir 52 Multi Ethnic Study 52 Patients Receiving 52 BLLs 52 aminotransferases 52 anticonvulsant medications 52 serum urate levels 52 pyridostigmine 52 progressive PsA 52 Antidepressant medications 52 CAMMS# 52 asymptomatic hypothyroidism 52 Chronic insomnia 52 lipid lowering therapy 52 Multivariate logistic regression 52 BCG vaccinated 52 Posttraumatic stress disorder PTSD 52 anticholinergic medications 52 thromboembolic complications 52 CVD mortality 52 hepatitis C genotype 52 MAS XR 52 Lumbar spine 52 symptomatic VTE 52 Sustained Efficacy 52 NATRECOR ® 52 sustained ventricular tachycardia 52 conjugated equine estrogen 52 Hp2 2 52 polysomnography PSG 52 silent myocardial ischemia 52 Premenopausal women 52 Fasting glucose levels 52 benazepril 52 Stenting Trial 52 logistic regression 52 prospective multicentre 52 olanzapine quetiapine 52 fetal chromosomal 52 Infarct 52 serum uric acid 52 BRCA1 mutations 52 placebo dexamethasone 52 AVODART 52 highest tertile 52 tipranavir r 52 glioma tumors 52 RE LY ® 52 osteoporotic vertebral compression fractures 52 fluvastatin 52 Sterilization Supplies Markets Independently 52 Exclusion criteria 52 postmenopausal women 52 HbA 1c levels 52 multivariate analyzes 52 primary generalized tonic 52 psychiatric outpatients 52 meta regression 52 male Sprague Dawley 52 hematopoietic cancers 52 common disabling neurological 52 cerebrovascular events 52 CI -#.# 52 kg m² 52 dapagliflozin plus 52 dopamine antagonists 52 febrile seizures 52 INVEGA ® 52 IIIa inhibitors 52 undergone hysterectomies 52 inhaled budesonide 52 ONGLYZA saxagliptin 52 prolonged QT intervals 52 noncardiac 52 Symptom severity 52 salivary cortisol 52 polyarticular 52 BARACLUDE ® 52 nonfatal MI 52 Sjögren syndrome 52 bulimia nervosa 52 underwent liver transplantation 52 asymptomatic PAD 52 thyroid dysfunction 52 randomized multicenter 52 VUR 52 Dietary Modification Trial 52 mixed hyperlipidemia 52 receiving antiretroviral therapy 52 #q#.# deletion syndrome 52 creatinine clearance 52 arthralgias 52 quetiapine Seroquel 52 nonfasting triglyceride levels 52 osteosarcomas 52 Ejection Fraction 52 GH deficient 52 citalopram Celexa 52 CDAI 52 PREMPRO 52 infliximab monotherapy 52 antiepileptic drugs AEDs 52 treatment emergent AEs 52 severe neutropenia 52 placebo controlled clinical trials 52 evaluable subjects 52 neurocognitive impairment 52 ß blockers 52 anemia hemoglobin 52 squamous histology 52 distal radial fractures 52 serum testosterone 52 glucose insulin 52 Severe acneform rash 52 colorectal bowel 52 semistructured interviews 52 carotid atherosclerosis 52 point Likert scale 52 hsCRP levels 52 mIU ml 52 Biopsies 52 moderate renal impairment 52 metabolic syndrome MetS 52 Atherosclerosis MESA 52 % Confidence Interval 52 HCV RESPOND 2 52 Hepatotoxicity 52 severe mitral regurgitation 52 Pediatric Patients 51 lowest tertile 51 chest radiographs 51 treatment naive genotype 51 ALT elevation 51 thromboembolic 51 Controlled Trial 51 nmol l 51 type2 diabetes 51 Sequenced Treatment Alternatives 51 mcg BID 51 ticlopidine 51 stable angina 51 EURIDIS 51 Thrombolysis 51 DAPT 51 Endothelial function 51 Evaluation WISE 51 Osteoporotic Fractures 51 digit dialed 51 Peptide YY 51 interpersonal psychotherapy 51 APOE genotype 51 liver histology 51 transaminase elevations 51 Endothelial Function 51 mild renal impairment 51 CI #.#-#.# [001] 51 chronic periodontitis 51 baseline serum creatinine 51 autonomic dysfunction 51 oral allopurinol 51 nondiabetics 51 febrile seizure 51 dysmenorrhea 51 elevated depressive symptoms 51 prospective nonrandomized 51 testicular tumors 51 serum estradiol 51 hyperlipidemia hypertension 51 verbal fluency 51 IN NATIONAL NEWS 51 Nesiritide 51 morphometric vertebral fractures 51 HGPIN 51 antiretroviral naive 51 gallstone disease 51 Somnolence 51 FDG PET imaging 51 nonfatal cardiac arrest 51 tibolone 51 hyperplasia BPH 51 Univariate analysis 51 activity MAOA 51 underwent prostatectomy 51 infliximab therapy 51 NSTE ACS 51 prospectively enrolled 51 mg kg dose 51 placebo controlled dose escalation 51 seropositivity 51 clomipramine 51 recurrent atrial fibrillation 51 CHD mortality 51 NORTH CAROLINA NEWS 51 Folfox 51 Chronic ITP 51 MACCE 51 abdominal adiposity 51 poststroke 51 Subgroup analyzes 51 estrogen progestin therapy 51 allele frequencies 51 hydroxyvitamin D levels 51 gastroesophageal reflux GERD 51 hypokalemia hypomagnesemia 51 convulsive disorders 51 generalized epilepsy 51 de aths 51 confidence interval CI 51 nonpsychotic 51 liver transplantations 51 mg RDEA# 51 hypogonadotropic hypogonadism 51 fluoxetine Prozac 51 Scale EDSS score 51 dopaminergic therapy 51 Mg Uk 51 DSM IV SCID 51 gestational diabetes mellitus 51 SSRI antidepressant 51 bortezomib refractory 51 abnormal genital 51 trials RCTs 51 intracranial hypertension 51 intima media thickness 51 POAG 51 cognitive domains 51 obese adolescents 51 BRCA1 mutation carriers 51 intravitreal injections 51 mania hypomania 51 ELBW 51 idiopathic PD 51 cardioembolic stroke 51 STRIDE PD 51 DLTs 51 DSM IV Axis 51 opioid prescriptions 51 Adjunctive Treatment 51 Sudha Seshadri MD 51 colorectal neoplasia 51 Crohn Disease Activity 51 timepoints 51 cGy 51 diarrhea predominant IBS 51 MGUS 51 National Epidemiologic Survey 51 Intervention Trial 51 chromium picolinate supplementation 51 tiagabine 51 budesonide pMDI 51 pimozide 51 binge eating disorders 51 somatoform disorders 51 deep venous thromboses 51 KRAS mutations occur 51 severe hypoglycaemia 51 BMD measurements 51 cervical spine fractures 51 atypical hyperplasia 51 specific antigen PSA 51 alanine aminotransferase ALT 51 telomere lengths 51 endometrial hyperplasia 51 BRCA2 carriers 51 Partial Onset Seizures 51 prolactin elevation 51 tacrolimus ointment 51 Multicenter AIDS 51 Mood disorders 51 recurrent seizures 51 multicentre prospective 51 ZACTIMA 51 QTcF 51 mU L 51 Paxil paroxetine 51 Nutrition EPIC 51 generalized estimating 51 preoperative evaluation 51 elevated LDL 51 YMRS 51 Asymptomatic 51 Parkinson disease PD 51 incontinence episodes 51 oxygen desaturation 51 Hypoactive Sexual Desire Disorder 51 #mg q8h 51 androgen deficiency 51 del 5q MDS 51 clozapine Clozaril 51 leucopenia 51 galiximab 51 Atypical antipsychotics 51 anticonvulsant medication 51 baseline LDH 51 Chronic Insomnia 51 ximelagatran 51 Binge eating 51 gastro oesophageal reflux disease 51 MIGRAINE 51 EEGs 51 mcg albinterferon alfa 2b 51 Infusion Reactions Severe 51 controlled dose escalation 51 placebo dummy pill 51 Hypogonadism 51 choline intake 51 juvenile idiopathic arthritis 51 prolactin levels 51 parous 51 pre menopausal 51 undergoing bariatric surgery 51 #OHD levels 51 TT genotype 51 IN MAINE NEWS 51 Teriflunomide 51 patients undergoing CABG 51 Pfizer Geodon 51 prospective observational studies 51 moderate hepatic impairment 51 rs# [001] 51 Aortic stenosis 51 #mmHg [001] 51 VTEs 51 plasma homocysteine 51 lifetime abstainers 51 faulty BRCA2 gene 51 non aspirin NSAIDs 51 MIRAPEX 51 bronchopulmonary dysplasia 51 pheochromocytoma 51 Brief Psychiatric 51 dietary calcium intake 51 ACR Pedi 51 ECOG PS 51 abnormal lipid levels 51 APOE e4 51 Adjunctive 51 LNG IUS 51 valproate 51 tonic clonic seizures 51 subclinical hyperthyroidism 51 PRADAXA 51 fructose diet 51 T2DM 51 antiepileptics 51 premenopausal women 51 severely cognitively impaired 51 uninfected infants 51 polyp recurrence 51 stage IIIb IV 51 metabolite concentrations 51 Female Sexual Function 51 kidney transplant recipients 51 neurodevelopmental outcomes 51 inattention hyperactivity 51 fewer uterine cancers 51 depressive symptom 51 hemodialysis patients 51 valvular disease 51 Folic Acid Supplements 51 Small Intestine 51 serum HCV RNA 51 monozygotic twin 51 Uterine cancer 51 Anxiety disorders 51 SUVmax 51 plus methotrexate 51 BRCA testing 50 follicular phase 50 microbleeds 50 acute subacute 50 mIU L 50 AGHD 50 alexithymia 50 Postmenopausal women 50 Often Misdiagnosed 50 metabolic syndrome clustering 50 CYPHER Stent 50 progesterone receptor negative 50 cilostazol 50 Fasting blood glucose 50 carotid artery blockage 50 mcg linaclotide 50 HBeAg negative patients 50 gross hematuria 50 ischemic strokes 50 smoldering myeloma 50 AIR CF1 50 clinically localized prostate 50 binary logistic regression 50 VLBW infants 50 hereditary predisposition 50 neurodevelopmental impairment 50 Low birthweight 50 Alzheimer disease vascular dementia 50 DEXA scan 50 paricalcitol 50 neuroimaging studies 50 clinically meaningful improvement 50 progressive neurodegenerative disorder 50 methylphenidate Ritalin 50 HAM D# scores 50 dietary intakes 50 newer antipsychotics 50 BRCA gene mutations 50 abdominal pain flatulence 50 DAS# [002] 50 glulisine 50 abdominal ultrasounds 50 ECASS 50 virologic breakthrough 50 postoperative atrial fibrillation 50 randomized controlled clinical trials 50 tipranavir ritonavir 50 paroxetine sertraline 50 HDL2 50 Isai Aguilar Morales 50 postintervention 50 lobular breast cancer 50 carotid artery stenting CAS 50 Cochrane reviewers 50 dosing cohorts 50 Relapsing remitting MS 50 neutrophil counts 50 subscale scores 50 Refractory Hodgkin Lymphoma 50 essential thrombocythemia 50 chlamydial infection 50 amisulpride 50 Antipsychotics 50 comparator arm 50 glomerular filtration 50 psychosocial functioning 50 noncardiac surgery 50 Dosages 50 generalized tonic clonic seizures 50 receiving VICTRELIS 50 #.#mmol l [002] 50 hyper IgE syndrome 50 ARCALYST ® rilonacept 50 GOUT 50 spontaneous preterm birth 50 generalized seizures 50 seronegative 50 RRMS patients 50 Ischemic 50 Slow Progression 50 cranial irradiation 50 endometriosis ovarian cysts 50 NHAMCS 50 % CI #.#-#.# [005] 50 sertraline Zoloft 50 subscores 50 definite stent thrombosis 50 mm Hg diastolic 50 abnormal cytology 50 CLA supplementation 50 severely active polyarticular 50 stepwise logistic regression 50 onset idiopathic hypogonadism 50 Obsessive compulsive disorder OCD 50 Dose limiting toxicities 50 weekly CSBMs 50 ACTEMRA TM 50 Nord Trøndelag Health 50 ng dL 50 impaired glucose metabolism 50 Hypertrophic cardiomyopathy 50 Platelet Inhibition 50 Relieve Depression STAR 50 carotid IMT 50 prevalences 50 severe exacerbations 50 mCi 50 PASI scores 50 susceptibility loci 50 HbA1c levels 50 NMIBC 50 Heritability 50 Platelet counts 50 amnestic mild cognitive impairment 50 postmenopausal hormone therapy 50 postoperative AF 50 IFN alfa 50 Relapsing Remitting Multiple Sclerosis 50 receiving INTRON 50 Calcium Intake 50 retinopathy nephropathy 50 GnRH agonists 50 diarrhea flatulence 50 revascularizations 50 Flu Cy 50 alfa 2a 50 serum vitamin D 50 ginkgo biloba extract 50 Depressive Symptoms 50 polytherapy 50 LEARN MORE ABOUT 50 Benign prostatic hyperplasia BPH 50 R# #mg BID 50 Androgen Deprivation Therapy 50 digital rectal examination 50 serum phosphate 50 Epidemiologic studies 50 Functional magnetic resonance 50 ApoE gene 50 Interpersonal psychotherapy 50 BENICAR HCT 50 prescribed statins 50 EXJADE 50 fatal myelination disorder 50 pharyngeal cancer 50 differentially expressed genes 50 partial onset seizures 50 mg administered orally 50 TAXUS ARRIVE 50 Primary endpoints 50 Pharmacokinetic parameters 50 lipid abnormalities 50 ejection fractions 50 tertiles 50 selective cyclooxygenase 2 50 urine albumin 50 physiologic responses 50 retrospective observational study 50 tricyclic antidepressants 50 AML MDS 50 familial hypercholesterolemia 50 #mg/dl 50 dose escalation phase 50 events SAEs 50 EFFEXOR XR 50 elevated transaminases 50 precancerous colon polyps 50 HMG CoA reductase inhibitors 50 refractory ischemia 50 systolic dysfunction 50 transcranial Doppler 50 System IPSS 50 MAGE A3 ASCI 50 PGTC seizures